Key Points
- Tempest CEO Matthew Angel acquired 231,482 shares on March 24 at an average price of $2.16 per share for about $500,001, and the purchase was disclosed in an SEC Form 4.
- Tempest is a micro‑cap biotech with a market cap of roughly $8.58 million and shares trading near $1.74 (52‑week range $1.65–$12.23; 50‑day/200‑day averages $2.41/$5.44); the stock carries a consensus "Reduce" rating and institutional ownership of about 22.5% with recent buys by Vanguard, Sabby and Dimensional.
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) CEO Matthew Angel acquired 231,482 shares of the company's stock in a transaction dated Tuesday, March 24th. The shares were bought at an average cost of $2.16 per share, with a total value of $500,001.12. Following the purchase, the chief executive officer owned 231,482 shares of the company's stock, valued at approximately $500,001.12. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Tempest Therapeutics Stock Performance
Shares of Tempest Therapeutics stock opened at $1.74 on Thursday. Tempest Therapeutics, Inc. has a 52-week low of $1.65 and a 52-week high of $12.23. The company's 50 day moving average price is $2.41 and its 200-day moving average price is $5.44. The stock has a market capitalization of $8.58 million, a price-to-earnings ratio of -0.17 and a beta of -2.42.
Institutional Investors Weigh In On Tempest Therapeutics
A number of large investors have recently modified their holdings of TPST. Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics during the fourth quarter valued at about $33,000. Vanguard Group Inc. raised its stake in Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company's stock worth $1,671,000 after buying an additional 27,952 shares in the last quarter. Finally, Sabby Management LLC purchased a new stake in Tempest Therapeutics in the fourth quarter worth about $513,000. Institutional investors own 22.52% of the company's stock.
Analyst Ratings Changes
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus target price of $12.50.
View Our Latest Report on TPST
Tempest Therapeutics Company Profile
(
Get Free Report)
Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.
The company's lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
